It's one thing to have your drug pulled from the market because of side effects. It's quite another to have it yanked for not being approved in the first place.
The FDA has ordered Baxter
The removal likely won't be a major blow to either company. For instance, Baxter said that the solution had peak annual sales of less than $1.5 million, compared to nearly $12 billion in revenue last year. Alcon
It's surprising how often drugs get pulled from the market for being unapproved. The agency estimates that about 2% of prescriptions in the U.S. are filled with unapproved drugs.
Fortunately, investors generally don't have to worry about the companies they own losing a major source of revenue by having an unapproved drug banned from the market. It's a little hard to become a major seller without getting noticed.
Sometimes, however, the drugs that get pulled can be bigger than you'd expect. Last year, the agency ordered about 20 companies to stop selling cough medicines that contained timed-released guaifenesin, the active ingredient in Adams Respiratory Therapeutics' Musinex (which is approved). K-V Pharmaceutical
While the most recent cease-order may not hurt sales at Baxter and Hospira that much, getting a drug pulled because it was never approved does say something about the company. Between unapproved drugs, tainted heparin, and recalls of its infusion pumps, Baxter's management isn't looking too competent right now.
Recall this previous Foolishness:
The team at Motley Fool Rule Breakers are always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.